Charles Bennett, an oncologist and cancer researcher whose work focuses on adverse events caused by pharmaceutical products, settled a federal complaint brought by a whistleblower alleging irregularities in the management of R01 research grants administered by Northwestern University.
The nation's academic cancer centers are a national resource that will increase in value as remarkable changes continue in biomedical research, cancer care, and health policy.
The Cancer Letter asked leaders of cancer centers, professional societies, and science advocacy organizations to comment on declining levels of NIH and NCI funding at freestanding cancer centers and selected academic institutions that include cancer centers.
The ten-year period of erosion that followed the doubling of the NIH budget has hit some research institutions harder than others.
FDA approved bortezomib (Velcade) injection for previously untreated patients with mantle cell lymphoma.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Anamorelin, a once-daily ghrelin receptor agonist, significantly increased lean body mass compared to placebo in two phase III trials in non-small cell lung cancer patients with cachexia.
A final analysis of a phase III trial showed that Zytiga (abiraterone acetate) plus prednisone significantly prolonged overall survival compared to an active control of placebo plus prednisone, in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.
Results from the LUX-Head & Neck 1 study showed that afatinib significantly delayed tumor growth compared to chemotherapy in patients following failure of their previous treatment, reducing the risk for disease progression by 20 percent.
A new analysis from the phase III SELECT trial of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer shows that the level of baseline angiopoietin-2 may be a predictive factor for lenvatinib response, tumor shrinkage and prolonged progression free survival. Angiopoietin-2 regulates the formation tumor blood vessels.